With 0.49 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.42 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $236.56 whereas the lowest price it dropped to was $227.93. The 52-week range on PEN shows that it touched its highest point at $277.34 and its lowest point at $148.00 during that stretch. It currently has a 1-year price target of $233.19. Beta for the stock currently stands at 0.51.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PEN was up-trending over the past week, with a rise of 13.97%, but this was up by 19.65% over a month. Three-month performance surged to 31.39% while six-month performance rose 11.87%. The stock gained 20.22% in the past year, while it has lost -7.25% so far this year. A look at the trailing 12-month EPS for PEN yields 0.86 with Next year EPS estimates of 3.77. For the next quarter, that number is 0.88. This implies an EPS growth rate of 33.08% for this year and 35.57% for next year. EPS is expected to grow by 24.68% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 66.20%.
Float and Shares Shorts:
At present, 38.68 million PEN shares are outstanding with a float of 37.06 million shares on hand for trading. On 2024-10-15, short shares totaled 2.65 million, which was 692.0 higher than short shares on 1726185600. In addition to Mr. Adam Elsesser as the firm’s Co-Founder, Chairman, President & CEO, Dr. Arani Bose M.D. serves as its Co-Founder & Director.
Institutional Ownership:
Through their ownership of 0.94421995 of PEN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PEN reported revenue of $301039000.0 and operating income of $35364000.0. The EBITDA in the recently reported quarter was $44262000.0 and diluted EPS was $0.75.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PEN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
